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Summary
The mechanisms controlling the transition from neu-
rogenesis to gliogenesis in the vertebrate CNS are
incompletely understood. We identified a family of
transcription factors, called NFI genes, which are in-
duced throughout the spinal cord ventricular zone (VZ)
concomitantly with the induction of GLAST, an early
marker of gliogenesis. NFIA is both necessary and suf-
ficient for GLAST induction in the VZ. Unexpectedly,
NFIA is also essential for the continued inhibition of
neurogenesis in VZ progenitors. This function ismedi-
ated by the requirement of NFIA for the expression
of HES5, a Notch effector. However, Notch effectors
are unable to promote glial-fate specification in the
absence of NFIA. Thus, NFIA links the abrogation of
neurogenesis to a generic program of gliogenesis, in
both astrocyte and oligodendrocyte VZ progenitors.
At later stages, NFIA promotes migration and differen-
tiation of astrocyte precursors, a function that is
antagonized in oligodendrocyte precursors by Olig2.
Introduction
Stem cells are uncommitted progenitors with the capac-
ity to both self-renew and to give rise to one or more dif-
ferentiated derivatives (Morrison et al., 1997). In some
stem cell lineages, such as the adult hematopoietic
system, multipotent progenitors produce their various
differentiated progeny concurrently (Morrison et al.,
1994). In other systems, however, multipotent stem
and progenitor cells generate different types of deriva-
tives on a defined schedule. In the developing central
nervous system (CNS), neurons are generated first,
followed by glia. The invariance of this developmental
sequence throughout the CNS, and its conservation
across vertebrate phylogeny, suggests that it involves
a fundamental mechanism. Despite the importance of
this ‘‘gliogenic switch,’’ however, its molecular basis is
poorly understood.
*Correspondence: wuwei@caltech.eduThe gliogenic switch is comprised of two related pro-
cesses: the inhibition of neurogenesis and the activation
of gliogenesis. A basic unresolved issue is the logic by
which these two processes are coordinated during the
switch. At one extreme, a unitary mechanism could
both prevent neurogenesis and promote gliogenesis
(Figure 1A1), as exemplified by the glial cells-missing
gene in Drosophila (Hosoya et al., 1995; Jones et al.,
1995; Vincent et al., 1996). At the other extreme, a distrib-
uted mechanism could operate, in which the abrogation
of neurogenesis serves a permissive function, while
a distinct, positive-acting factor instructs the glial pro-
gram (Figure 1A2). A distributed mechanism could also
involve independent processes, which are nevertheless
linked in some manner (Figure 1A3).
A number of studies have been interpreted to suggest
that inhibition of neurogenesis is sufficient to trigger the
onset of gliogenesis. The Notch pathway inhibits neuro-
genesis in embryonic CNS progenitors (Chitnis et al.,
1995). The mechanism of this inhibition involves the in-
duction of transcriptional repressors, such as HES
genes, that prevent the expression of proneural genes,
such as the neurogenins (Ngns) (reviewed in Louvi and
Artavanis-Tsakonas, 2006). Notch signaling has been
shown to be necessary for the generation of glial cells,
and gain-of-function manipulations of Notch and its
effectors often yield an increased number of glial cells
(Ishibashi et al., 1994; Ohtsuka et al., 1999; Gaiano
et al., 2000; Ohtsuka et al., 2001; Satow et al., 2001;
Zhou et al., 2001; Park et al., 2002; Hatakeyama et al.,
2004). However, these genetic experiments do not dis-
tinguish whether Notch signaling directly controls the
gliogenic switch or rather indirectly influences this pro-
cess by controlling the size of the undifferentiated pro-
genitor pool (Androutsellis-Theotokis et al., 2006).
The idea that the abrogation of neurogenesis is suf-
ficient to initiate gliogenesis has received additional
support from in vitro studies indicating that Ngn1, in
addition to its proneuronal function (Ma et al., 1998),
actively inhibits astrogliogenesis by blocking the JAK/
STAT pathway (Sun et al., 2001; He et al., 2005), which
in turn controls the expression of GFAP (Bonni et al.,
1997; Kahn et al., 1997; Nakashima et al., 1999). Accord-
ing to this model, downregulation of Ngns would relieve
inhibition of the JAK/STAT pathway, thereby inducing
gliogenesis essentially by default. However, GFAP is
a terminal astrocyte differentiation marker that is not ex-
pressed until several days after glial precursors have
emigrated from the ventricular zone (VZ), where the glio-
genic switch occurs. Furthermore, evidence that this
mechanism controls the initial specification of the glial
fate in vivo is limited. Double deletions of proneural
genes increase the extent of astroglial differentiation
in vivo, but precocious appearance of astrocytes was
not consistently observed (Nieto et al., 2001). Therefore,
while disinhibition of the JAK/STAT pathway may be
necessary for terminal astrocyte differentiation, it is
not clear whether it controls the initial gliogenic switch
in the VZ. Indeed, no transcription factor has been iden-
tified that is sufficient to promote the initial specification
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954Figure 1. NFIA and NFIB Are Induced in the
VZ at the Onset of Gliogenesis
(A) Models depicting possible mechanisms
controlling the gliogenic switch: (A1) a single
factor both inhibits neurogenesis and pro-
motes gliogenesis; alternatively, gliogenesis
could proceed by a default mechanism. (A2
and A3) Distinct factors inhibit neurogenesis
(a) and promote gliogenesis (b) in either an
independent (A2) or linked (A3) manner.
(B) Microarray-based quantification of NFIA
and NFIB induction in isolated Olig2-GFP+
progenitors.
(C–L) Analysis of NFIA/B expression in murine
embryonic spinal cord. (C–F) Expression of
NFIA (C and D) or NFIB (E and F) proteins de-
tected by immunostaining. White arrows (D
and F) indicate expression in the VZ, arrow-
head (D) expression in motoneurons. (G–L)
In situ hybridization for NFIA and NFIB
mRNAs. Arrows (H and K) denote expression
in the VZ, arrowheads expression in moto-
neurons.
(M–O) Fluorescent in situ hybridization for
mGLAST mRNA. Note that induction of
GLAST (N) coincides with that of NFIA/B (H
and K).
(P–U) Expression of NFI proteins detected by
immunostaining in the embryonic chick spi-
nal cord.
(V–X) In situ hybridization analysis for
cGLAST mRNAs. Note that upregulation of
GLAST in the VZ at E5 (W) coincides with in-
duction of NFIA (Q).
(Y–AA) Double-label fluorescent in situ for
NFIA and GLAST.of the glial fate in the VZ, in vivo. The HMG box transcrip-
tion factor Sox9 is required for the proper timing of glio-
genesis throughout the spinal cord (Stolt et al., 2003).
However, Sox9 is not sufficient to promote gliogenesis
in vivo (B.D. and D.J.A., unpublished data).
Here we show that NFIA and NFIB, members of a fam-
ily of CCAAT box element-binding transcription factors
(Gronostajski, 2000), are both necessary and sufficient
to promote glial-fate specification in embryonic spinal
cord progenitors, in vivo. In contrast to Notch effectors,
such as HES genes, NFI genes are not sufficient to
inhibit neurogenesis. Unexpectedly, however, NFIA is
required for the continued inhibition of neurogenesis in
VZ progenitors. This function is mediated by the require-
ment of NFIA for the expression of HES5, a Notch effec-
tor. However, Notch effectors are unable to promote
glial-fate specification in the absence of NFIA. Thus,
NFIA links the abrogation of neurogenesis to a generic
program of gliogenesis, in both astrocyte and oligoden-
drocyte VZ progenitors.
The requirement for NFIA in the oligodendrocyte line-
age is mediated by its requirement for the maintenance
of expression of Olig2 (Lu et al., 2002; Zhou and Ander-
son, 2002). Paradoxically, however, at later stages NFIA/
B promote terminal astrocyte differentiation. This dual
and sequential role requires a mechanism to suppressNFIA function in oligodendrocyte precursors (OPs). We
show that this proastrocytic function of NFIA is antago-
nized by Olig2, by a mechanism that likely involves
direct protein-protein interactions. These data suggest
that the gliogenic switch has an intrinsic astrocytic bias,
upon which the oligodendrocyte fate is superimposed
by Olig2.
Results
NFIA and NFIB Are Induced at the Onset of
Gliogenesis throughout the Developing Spinal Cord
To identify candidate genes associated with the switch
from neurogenesis to gliogenesis, we compared the
gene expression profiles of Olig2+ progenitors isolated
at different times spanning this developmental transition
(Lu et al., 2002; Zhou and Anderson, 2002; Mukouyama
et al., 2006). Olig2-GFP+ progenitors were purified
by FACS from the embryonic spinal cord of Olig2-
GFP knockin mice, at neurogenic stages (E9.5–E10.5)
and at early gliogenic stages (E11.5–E12.5) (see
Figure S1A, arrows, in the Supplemental Data available
online). cRNA probes were generated from total RNA
isolated from these different purified progenitor popula-
tions and hybridized to Affymetrix microarrays (see the
Supplemental Experimental Procedures). Among the
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of gliogenesis were nuclear factor I-A (NFIA) and nuclear
factor I-B (NFIB) (Figure 1B). These proteins are mem-
bers of a family of CAATT box-binding transcription fac-
tors, whose DNA-binding domains are distinct from
those of other CCAAT box element-binding proteins
(C/EBPs) (Meisterernst et al., 1988; Bandyopadhyay
and Gronostajski, 1994; Gronostajski, 2000). To validate
the microarray data, we performed immunostaining us-
ing antibodies specific for NFIA and NFIB (Figures 1C–
1F), as well as in situ hybridization for NFIA and NFIB
transcripts (Figures 1G–1L), on mouse embryo spinal
cord sections between E9.5 and E12.5. Expression of
NFIA and B in the VZ is first detected at E11.5–E12.5
(Figures 1D, 1F, 1H, and 1K, arrows), coincident with
the induction in the VZ of GLAST, an early astrocyte pre-
cursor (AP) marker (Shibata et al., 1997; Ogawa et al.,
2005) (Figures 1G, 1H, 1J, and 1K versus Figures 1M
and 1N). Expression of NFIA/B is initially highest in
more ventral regions of the VZ (Figures 1D, 1F, and 1H,
arrows) but later expands to cover the entire neuroepi-
thelium (Figure 1I and data not shown). NFIA/B are
also transiently expressed in a subset of differentiated
motoneurons at E11.5–E12.5 (Figures 1D, 1H, and 1K,
arrowheads).
Although we initially identifiedNFIA/B by their upregu-
lation in Olig2+ oligodendrocyte progenitors, their induc-
tion throughout the VZ raised the possibility that they
might play a more general role in early gliogenesis. To
address this question, we sought to carry out in vivo
gain-and loss-of-function (GOF and LOF) experiments,
in the embryonic chick neural tube. As a first step, we
characterized the expression of NFIA and NFIB in this
avian system. As in the mouse, NFIA/B expression was
not detected in the VZ at neurogenic stages (E3–E4)
(Figures 1P and 1S; cf. Figures 1C and 1E) but by E5
was expressed throughout the VZ (Figure 1Q, arrow).
The induction of NFIA followed that of cHES5, a Notch
effector (Fior and Henrique, 2005), by 1–2 days (Fig-
ure S1G–S1L). Unlike the case in mouse, the induction
of NFIB expression in chick lags behind that of NFIA
by w24 hr (Figures 1Q, 1T, and 1U). As in the mouse,
however, the timing of NFIA induction was coincident
with the upregulation in the VZ of GLAST (Figures 1P
and 1Q versus Figures 1V and 1W), although a low level
of GLAST mRNA was detectable at E4. Double-label in
situ hybridization experiments confirmed that NFIA
and GLAST overlap in the VZ (Figures 1Y–1AA), as do
Olig2 and GLAST (not shown). Importantly, while neu-
rons continue to be generated in dorsal regions of the
neural tube at cE6, the expression of NFIA in these
regions is mutually exclusive with that of neuronal pre-
cursor markers such as Lim1/2 (Figures S1E and S1F;
yellow arrows versus white arrowheads) (Liem et al.,
1995; Muller et al., 2002). Taken together, these data
indicate that the onset of NFIA induction in the VZ is
correlated with the emergence of progenitors fated to
become glia (Figure 9A) and suggest that NFIA is likely
to mark such gliogenic progenitors.
Misexpression of NFI Genes Promotes Glial-Fate
Specification without Repressing Neurogenesis
The observation that the onset of NFIA is tightly corre-
lated with the upregulation of GLAST in the VZ raised thequestion of whether this factor plays an instructive role
in the acquisition of glial identity by VZ progenitor popu-
lations. To address this question, we asked whether mis-
expression of an NFIA cDNA could accelerate the timing
and/or increase the extent of glial differentiation in vivo.
Misexpression of NFIA caused a precocious upregula-
tion of GLAST mRNA in the VZ at E4 (Figures 2A and
2E; arrow) and increased expression in the VZ at E5 (Fig-
ures 2B and 2F; arrow; Figure 2AA). Misexpression of
NFIB produced a similar phenotype (Figures 2I, 2J,
2M, and 2N, arrows). In contrast, the expression ofOlig2,
which is already present in the VZ prior to the induction
of NFIA, was unaffected by misexpression of NFIA or
NFIB (Figures S2G and S2J). Misexpression of NFIA
did not change the timing or extent of NFIB expression
(data not shown).
In addition to promoting precocious expression of
GLAST in the VZ at E4, misexpression of NFIA or NFIB
increased the number of GLAST+ cells migrating from
the VZ into the gray matter at E6–E7 (Figures 2G, 2H,
2O, and 2P; arrows; Figure 2Y). A similar increase was
observed using FGFR3 (Pringle et al., 2003) and FABP7
(Bisgrove and Godbout, 1999) as markers of migrating
APs (Figures S2S–S2Z). This effect was not due simply
to enhanced proliferation of APs, as no change in the
number of proliferating cells, as assessed by staining
for PCNA, was observed (data not shown). Coelectropo-
ration of NFIA and NFIB did not further enhance the phe-
notype obtained with either gene singly (Figure 2Y and
data not shown). NFIA or NFIB did not increase the num-
ber of Olig2+ or PDGFRa+ migrating OPs (Figures S2I,
S2L, S2O, and S2R). Thus, NFIA/B misexpression not
only accelerated GLAST induction throughout the VZ
but also specifically promoted AP migration into the
gray matter.
Since misexpression of NFIA/B led to a precocious in-
duction of GLAST in the VZ, we next assessed whether it
concurrently repressed neuronal markers. Misexpres-
sion of NFIA or NFIB had no effect on the number of
neurogenin2- (Ngn2) or NeuN-expressing cells at E5
(Figures 2R, 2S, and 2Z and data not shown). Thus,
NFIA/B can promote gliogenesis in a manner indepen-
dent of any effect to inhibit neurogenesis. It has previ-
ously been shown that misexpression of Notch pathway
components, which inhibit neurogenesis, can promote
astroglial differentiation (reviewed in Louvi and Artava-
nis-Tsakonas, 2006). To determine whether such a
manipulation could phenocopy the effect of NFIA/B mis-
expression in this system, we coelectroporated plas-
mids encoding the Notch-intracellular domain (NotchICD)
and its coactivator suppressor of hairless (SuH). As
expected (Ma et al., 1996; Artavanis-Tsakonas et al.,
1999; Mumm and Kopan, 2000; Zhou et al., 2001;
Kageyama et al., 2005), this manipulation strongly re-
pressed expression of both Ngn2 and NeuN (Figures
2U–2W and 2Z). By contrast, it did not cause an upregu-
lation or precocious appearance of GLAST in the VZ
(Figures 2X and 2AA). Thus, the mere inhibition of neuro-
genesis, via activation of Notch signaling, does not phe-
nocopy the ability of NFIA to accelerate the induction
of GLAST in the VZ. These data suggest that inhibition
of neurogenesis by Notch effectors is not sufficient
to trigger the gliogenic switch, prior to the appearance
of NFIA.
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(A–H) Misexpression of HA-mNFIA analyzed by anti-HA antibody staining (A–D) or GLAST in situ (E–H). Note upregulation of GLAST in the VZ at
E4–E5 ([E and F], arrows). Note also precocious migration of GLAST+ cells at E6–E7 ([G and H], arrows). (I–P) Similar analysis for HA-mNFIB. Data
are representative of at least six embryos from four independent experiments. (Q–T) Misexpression of NFIA and (U–X) NotchICD/SuH, compar-
ative analysis of ngn2 (R and V), NeuN (S and W), and GLAST (T and X). (Y) Quantification of the number of migrating GLAST+ cells at E7. (Z) Quan-
tification of the number of ngn2-expressing cells at E5. (AA) Quantification of the intensity of GLAST expression in the VZ at E5. Values are nor-
malized to the nonelectroporated side and derive from at least five sections per embryo from three independent experiments. Scale bar (A) is for
all panels. Error bars indicate SD.NFIA Expression Is Necessary for the Gliogenic
Switch
We next examined the requirement of NFIA/B for glial-
fate specification. To do this, we focused on NFIA, be-
cause its induction precedes that of NFIB in the chick.
To inhibit NFIA expression, we utilized an RCAS-based
shRNAi system. The effective knock-down of endoge-
nous chick NFIA in the VZ was verified by antibody stain-
ing (Figures 3F and 3G; arrows). Knock-down of NFIA
clearly inhibited the expression of GLAST mRNA begin-
ning on E5 (Figures 3J and 3K, arrows). However, the low
level of GLAST mRNA detectable at E4 was unaffected,
despite the expression of the NFIA-shRNAi construct at
this earlier stage (Figures 3A and 3I). A similar phenotypewas observed using FGFR3, an AP marker (Pringle et al.,
2003) that is expressed both prior to and following NFIA
induction in the VZ (Figures 3Q, 3R, and 3S; arrow;
Figures S1B–S1D). NFIA knock-down also prevented
the induction of NFIB at E6 (Figure 3O, arrow). Thus,
the NFIA-directed shRNAi prevented the expression in
the VZ of multiple astroglial precursor markers.
Olig2, which marks the oligodendrocyte progenitor
domain in the VZ (Lu et al., 2000; Zhou et al., 2000), is
also expressed prior to NFIA induction at E5, reflecting
its earlier role in motoneuron-fate specification (Mizugu-
chi et al., 2001; Novitch et al., 2001). As in the cases of
GLAST and FGFR3, expression of Olig2 was unaffected
by the NFIA shRNAi at E4 (Figure 3U) but was lost on the
NFI Genes Control the Gliogenic Switch
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Causes Loss of Glial Progenitor Markers in
the VZ
(A–D) Expression of the RCAS-cNFIA-shRNAi
construct on the electroporated (Ep) side of
the neural tube detected by immunostaining
for the retroviral coat protein AMV. (E–H) Ex-
pression of endogenous NFIA is inhibited by
the cNFIA-shRNAi ([F and G], arrows), but
not by the mutant shRNAi (H). (I–P) Upregula-
tion of GLAST mRNA ([J and K], arrows) and
of NFIB protein ([O], arrow) is prevented by
the NFIA-shRNAi, but not by the mutant
shRNAi ([L and P], arrows). (Q–X) Expression
of FGFR3 mRNA (Q–T) and of Olig2 protein
(U–X) is blocked beginning at E5 ([R and V],
arrows), but not at E4 (Q and U). Data are rep-
resentative of at least six embryos from four
independent electroporation experiments.
Marker analysis at each individual timepoint
represents adjacent sections (i.e., E4-A, E, I,
M, Q, U). (Y–CC) Rescue of the shRNAi phe-
notype by murine NFIA at cE6. Arrows (Z–
CC) indicate regions where high expression
of mNFIA (Z) prevents loss of GLAST (AA),
FGFR3 (BB), and Olig2 (CC). Inset (CC) indi-
cates overlap of HA-mNFIA (red) with Olig2
(green). Green arrowheads (Z–BB) indicate
regions where lower levels of mNFIA (Z) fail
to rescue expression of GLAST or FGFR3.
Data are representative of four embryos
from three independent electroporation ex-
periments. Scale bar (D) is for all panels.electroporated side at E5 and E6 (Figures 3V and 3W, ar-
rows). These data suggested that NFIA knock-down not
only prevents the expression of astroglial precursor
markers that are induced or upregulated at E5 and later
(GLAST, NFIB) but also extinguishes markers of both as-
trocyte (FGFR3) and oligodendrocyte (Olig2) precursors,
which are initially expressed at earlier stages.
The fact that the NFIA-RNAi inhibited FGFR3 and
Olig2 expression after, but not before, the time of en-
dogenous NFIA induction at E5, despite the fact that
electroporation was performed several days earlier(E2), suggested that this phenotype reflects specific
NFIA knock-down. To assess further the specificity of
the NFIA-RNAi phenotype, two types of control experi-
ments were performed. First, we tested a mutant NFIA
shRNAi, containing four nucleotide substitutions, which
had no effect on NFIA expression (Figures 3D and 3H,
arrow). This mutant NFIA-RNAi did not alter the expres-
sion of GLAST, NFIB, FGFR3, or Olig2 (Figures 3L, 3P,
3T, and 3X; arrows). Second, the cNFIA shRNAi con-
struct was coelectroporated with a ‘‘rescue’’ construct
containing the murine NFIA (mNFIA) coding sequence,
Neuron
958Figure 4. RNAi Knockdown of Chick NFIA Causes Loss of Multiple Progenitor Markers in the VZ
(A–D) Immunostaining for Pax6; blue nuclear counterstain (A–D) is Topro-3. (T) Quantification is expressed as percentage of Topro-3+ nuclei ex-
pressing indicated marker. See Figure S3 for Pax7 and Sox9 (outside pMN). (E–H and U) Cell loss in the VZ after E4 is revealed by Topro-3 stain-
ing. (I–L and V) Immunostaining for activated caspase-3. (M–P and W) Double immunostaining for Olig2 and Sox9. (Q and R) Immunostaining
detecting knockdown of NFIA and co-misexpression of p35. (S) In situ hybridization detecting GLAST expression. Note that coelectroporation
of p35 with the NFIA-RNAi inhibited cell death (H and U and L and V) but did not effect the expression of VZ markers (D and T; P and W; and S and
X). Data are representative of at least six embryos from four independent experiments. Quantitative analysis in (T)–(X) represents at least three
sections per embryo times three embryos, for each experimental condition and time point. (A) ‘‘Ep’’ indicates electroporated side of the neural
tube, ‘‘Con’’ control side. Scale bar (B) is for panels (A)–(P). Error bars indicate SD.which is sufficiently divergent from the chick sequence
so as not to anneal with the cNFIA-shRNAi. An HA
epitope tag was included to report expression of the
exogenous mNFIA protein. In regions of the VZ contain-
ing high levels of ectopic HA-mNFIA (white arrow,
Figure 3Z), inhibition of GLAST, FGFR3, and Olig2 by
the cNFIA-shRNAi was suppressed (black arrows, Fig-
ures 3AA and 3BB; white arrow, Figure 3CC). Conversely,
in regions of the VZ that lacked sufficiently high levels of
ectopic HA-mNFIA expression (Figure 3Z, green arrow-
head), expression of GLAST and FGFR3 was still in-
hibited by the cNFIA-shRNAi (Figures 3AA and 3BB,
green arrowheads). Taken together, these three lines of
evidence strongly suggest that knock-down of endoge-
nous NFIA is responsible for the reduction of GLAST,
FGFR3, and Olig2 caused by the cNFIA-shRNAi.
NFIA Is Necessary for Progenitor Maintenance
in the VZ during the Gliogenic Phase
The foregoing results led us to investigate whether the
maintenance of other VZ progenitor markers, whichlike Olig2 are expressed throughout the neurogenic-
gliogenic transition, becomes dependent on NFIA after
E5. Such markers include Pax6, Pax7, and Sox9. In em-
bryos electroporated with the NFIA-shRNAi, there was
a 60% reduction in the number of Pax6-expressing cells
at E5, but not at E4 (Figures 4A, 4C, and 4T). A further re-
duction was seen at E6 (data not shown). There was also
an w40% reduction in the number of Sox9+ cells at E5
(Figure 4O, green nuclei; Figure 4W and Figures S3F–
S3J and S3L). A reduction in Pax7 expression was also
observed, although this did not become apparent until
E6 (Figures S3A–S3E and S3K). In all cases, the loss of
markers was not observed in embryos electroporated
with the mutant RNAi (Figures 4B and 4N; Figures S3B,
S3G, S3D, and S3I).
One possible explanation for the loss of multiple VZ
markers in the absence of NFIA is cell death. The total
number of Topro-3+ nuclei on the NFIA shRNAi-electro-
porated side was reduced by 40% at E5 (Figures 4G and
4U). In addition, the expression of activated caspase3, a
marker of apoptosis (Villa et al., 1997; Thornberry and
NFI Genes Control the Gliogenic Switch
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rated side of the neural tube at E5, compared to the con-
tralateral control side (Figures 4K and 4V). Elevated
levels of activated caspase3 were not observed in
NFIA shRNAi-electroporated embryos at E4 (Figures 4I
and 4V) or in E5 embryos electroporated with the control
(mutant) NFIA-shRNAi (Figure 4J). Together, these data
indicate that NFIA knock-down specifically promotes
gradual apoptosis in the VZ, beginning on E5.
The initial loss of marker expression observed in the
VZ of NFIA knock-down embryos is not, however, due
to apoptosis, as indicated by two lines of evidence. First,
if marker loss were due exclusively to cell death, then all
markers at a given position along the D-V axis should be
coordinately extinguished. However, this is not the case:
at ventral levels of the VZ, double-labeling for Sox9 and
Olig2 indicates that these two markers are lost to signif-
icantly different extents in NFIA-shRNAi embryos, even
though all Olig2+ cells are Sox9+ (Figures 4O and 4W).
Second, coelectroporation of the NFIA-RNAi with the
antiapoptotic protein p35 (Figures 4Q and 4R) (Miller,
1997; Araki et al., 2000) reduced the number of activated
caspase3-expressing cells (Figure 4K versus Figures 4L
and 4V) and restored the number of Topro3+ nuclei in the
VZ (Figure 4G versus Figures 4H and 4U), but did not re-
store the normal expression of Pax6, Olig2, and Sox9
(Figure 4C versus Figures 4D, 4T, and 4O versus Figures
4P and 4W). Similarly, the loss of GLAST expression
caused by NFIA knock-down was not restored by inclu-
sion of p35 (Figures 4S and 4X). Taken together, these
data indicate that NFIA is not only required for the induc-
tion of glial precursor markers in the VZ, but also for the
maintenance of a battery of neural progenitor markers,
whose expression is initiated several days before NFIA
itself is induced.
Genetic Uncoupling of NFIA Function in Gliogenesis
and Progenitor Maintenance
In the course of staining NFIA-shRNAi embryos with an-
tibodies to the pan-neuronal marker NeuN, we noticed
numerous NeuN-positive cells intercalated into the neu-
roepithelium on the electroporated side (Figures 5A, 5B,
and 5K; Ep), while on the contralateral control side such
cells were separated from the ventricle by the VZ
(Figure 5A, 5B, and 5K; Con). These observations could
indicate a conversion of VZ progenitors to newly differ-
entiated neurons or a migration into the VZ by previously
differentiated neurons. Active neurogenesis can be as-
sessed by the incorporation of BrdU into dividing neuro-
nal precursors. Therefore, we performed a BrdU pulse-
labeling experiment at E5 in NFIA-shRNAi embryos
(Figure 5X). In such embryos, numerous BrdU+/NeuN+
cells were observed on the electroporated side, while
practically none were present on the contralateral con-
trol side (Figures 5E–5G, arrows; Figure 5Y). These
data suggest that, while NFIA is not sufficient to inhibit
neurogenesis when misexpressed, it may nevertheless
be required for the inhibition of neurogenesis in the VZ.
We next sought to delineate the mechanism by which
NFIA is required to inhibit neurogenesis. The ectopic
neurogenesis in the VZ observed following NFIA knock-
down resembled what one might expect if Notch signal-
ing were compromised. Indeed, inhibition of Notch
signaling, via misexpression of a dominant-negativeversion of SuH (SuHDBM; Wettstein et al., 1997; Fior
and Henrique, 2005), yielded a phenotype similar to
that of the NFIA-shRNAi knock-down (Figures 5A and
5B versus Figures 5C and 5D). These data raised the
possibility that NFIA might be required for the expres-
sion of one or more components of the Notch signaling
pathway. Because HES proteins are the most proximal
inhibitors of neurogenesis in the Notch pathway, we in-
vestigated whether NFIA is required for the expression
of HES genes in the VZ (Ishibashi et al., 1995; Hata-
keyama et al., 2004). Knock-down of NFIA (in the pres-
ence of p35) led to a clear loss of cHES5 expression (Fig-
ure 5H, arrow; Figure 5Z). These data suggested that the
requirement of NFIA for the inhibition of neurogenesis
might be explained by its requirement for the expression
of HES genes or of other Notch pathway elements.
To investigate further this hypothesis, we asked
whether constitutive expression of Notch pathway com-
ponents could rescue the NFIA-RNAi phenotype in the
VZ. To this end, we coelectroporated the NFIA-shRNAi
construct together with either a combination of NotchICD
and SuH or with a rat-Hes cDNA. Both NotchICD/SuH and
Hes were able to suppress the ectopic VZ neurogenesis
caused by NFIA knock-down (Figures 5K, 5P, and 5U),
without affecting the loss of NFIA itself (Figures 5I, 5N,
and 5S). Strikingly, NotchICD/SuH and Hes were also
both able to restore expression of the progenitor
markers Olig2, Sox9, and Pax6 (Figures 5L, 5Q, 5V,
and 5BB; Figures S4A–S4D). They also prevented the
cell death caused by NFIA knock-down in the absence
of p35 (data not shown). However, constitutive Notch
pathway activation did not prevent loss of the glial pro-
genitor marker GLAST in the VZ (Figures 5M, 5R, 5W,
and 5AA). These data reveal a genetic uncoupling be-
tween the roles of NFIA in progenitor maintenance and
in glial-fate specification. Notch effectors are sufficient
to bypass the requirement for NFIA in the former func-
tion, but not in the latter.
NFI Genes Promote the Progression of Astrocyte
Differentiation
As described earlier, misexpression of NFIA not only ac-
celerates and augments the expression of GLAST in the
VZ but also causes precocious and increased emigra-
tion of APs into the gray matter (Figures 2G, 2H, 2O,
and 2P; Figure S2). This latter phenotype raised the
question of whether NFIA has a later function in APs.
To investigate this possibility, we first examined whether
NFI genes continue to be expressed by migrating APs. In
E10 chick embryos, we observed numerous NFIA- and
NFIB-expressing cells in the gray matter that coex-
pressed GLAST or FGFR3 (Figures S5A–S5D). Similarly,
in the E15.5 and E18.5 mouse spinal cord, NFIA/B are
expressed in cells that appear to be migrating from the
VZ into the gray matter (Figures 6A–6D, arrows), and
many such cells coexpress s100b and GFAP, two
later-appearing astrocyte markers (Figures 6E–6H, ar-
rows). By E18.5, 80%–85% of GFAP+ cells coexpressed
NFIA or NFIB (Figure 6I and data not shown).
It has been previously reported that NFIA- and NFIB-
deficient mice exhibit decreased levels of GFAP mRNA
expression in the adult brain, as measured via qRT-
PCR (das Neves et al., 1999; Steele-Perkins et al., 2005).
Similarly, in E18.5 NFIA2/2 and NFIB2/2 embryonic
Neuron
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(A–D) Immunostaining for NeuN on chick embryos electroporated with either NFIA-RNAi+p35 (A and B) or SuHDBM (C and D), counterstained with
Topro3. (E–G and Y) Double immunostaining for BrdU and NeuN on NFIA-RNAi + p35 electroporated embryos treated with BrdU (X). (H and Z) In
situ hybridization of cHes5, red arrow marks loss of Hes5 expression. (N–W; AA–BB) Immunostaining and in situ hybridization analysis of NFIA-
RNAi coelectroporated with Hes (N–R) or NotchICD/SuH (S–W). Quantitative analysis in (Y)–(BB) represents at least five sections per embryo times
three embryos, for each experimental condition and time point. Panels (I) and (J) and (L) and (M) are reproduced from Figure 4 and are included to
facilitate comparison with (N)–(W). ‘‘Ep’’ indicates electroporated side of the neural tube, ‘‘Con’’ control side. Error bars indicate SD.spinal cord, there was anw70% andw50% decrease in
the levels of GFAP expression, respectively, as mea-
sured by immunostaining (Figures 6J–6M and 6R). This
reduction in GFAP expression is not due to cell death
or cell loss, because there was no change in the total
number of cells or in the number of astrocytes, as deter-
mined by expression of the complementary NFI protein
(Figures 6N–6Q and 6S). Examination of GFAP expres-
sion in NFIA; NFIB double-homozygous embryos was
not possible, because the two genes are closely linked,
and the single-gene knockouts were independently gen-
erated. Thus, the partial reduction in GFAP expression in
the single mutants likely reflects compensation by re-
maining NFI genes (see GOF data below).
We next asked whether misexpression of NFIA/B is
sufficient to promote precocious induction of GFAP,
in vivo. Expression of GFAP in the embryonic chick neu-
ral tube is normally not detected until E10–E11 (Agius
et al., 2004). In embryos electroporated with NFIA or
NFIB, by contrast, GFAP expression was observed as
early as E7 (Figures 6T–6Y and 6Z). The GFAP+ cells
in these E7 embryos coexpressed exogenous mNFIAand mNFIB, (as detected by an HA epitope tag; Figures
6X and 6Y), indicating that misexpression of these
factors accelerates GFAP expression in a cell-autono-
mous manner. Taken together, these data suggest that
NFIA/B not only control the initial specification of astro-
glial and oligodendroglial progenitors in the VZ but
also play a later and selective role in terminal astrocyte
differentiation.
Olig2 Antagonizes the Proastrocytic Function of
NFIA/B
The initial requirement of NFIA for Olig2 expression in
the VZ seemed paradoxical given the ability of NFIA/B
to promote astrocyte differentiation and the fact that
most Olig2+ glial progenitors are fated to become oligo-
dendrocytes (Lu et al., 2002; Zhou and Anderson, 2002;
Masahira et al., 2006). One simple solution to this para-
dox would be that NFIA/B is selectively repressed in
the oligodendrocyte lineage, at later stages of develop-
ment. Indeed, while >90% of Olig2+ cells in the VZ
are NFIA/B+ at E12.5 (Figures 7A–7D and 7I), by E18.5
only w40% of Olig2+ cells are NFIA/B+ (Figures 7E–7I).
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(A–D) Immunostaining for NFIA (A and B) and NFIB (C and D) on murine spinal cord at the indicated stages. Arrows indicate presumptive migrat-
ing cells. (E–H) Double immunostaining for NFIA/B and s100b (E and G) or GFAP (F and H) at E18.5. (I) Quantification of the percentage of GFAP+
cells coexpressing NFIA or NFIB, based on cytospin analysis of acutely dissociated E18.5 spinal cord. Values represent the mean of two inde-
pendent experiments. (J–S) Immunostaining of NFIA or NFIB +/2 and2/2 embryos with GFAP (J–M), NFIB/Topro3 (N and O), and NFIA/Topro3
(P and Q). Quantitative analysis (R and S) represents at least two embryos from two different litters of each genotype. (T–Y) Misexpression of HA-
mNFIA (T, U, and X) or HA-mNFIB (V, W, and Y) in chick embryos accelerates the onset of GFAP expression byw3 days. Data are representative
of at least six embryos from four independent experiments. (Z) The relative number of GFAP+ cells on the electroporated (Ep) side at E7 is in-
dicated (control side = 1). NFIA or NFIB + Olig2 indicate that an Olig2 expression construct was coelectroporated. Data are derived from at least
six sections per embryo times four embryos from three independent experiments. Error bars indicate SD.In Olig22/2 embryos, by contrast, most Olig2-GFP+ cells
continued to express NFIA/B at E18.5 (Figures S5E–
S5M), reflecting the conversion of oligodendrocyte pre-
cursors (OPs) in these embryos to GFAP+ astrocytes
(Zhou and Anderson, 2002). These data suggest that
NFIA/B is indeed downregulated in at least some OPs
following migration into the gray matter and suggestthat Olig2 itself plays a role (directly or indirectly) in
this repression.
Although loss of NFIA/B expression can account for
w60% of the Olig2+ OPs at E18.5, the fate of the
Olig2+ cells that continue to coexpress NFIA/B remained
unclear. We reasoned that in many of these coexpress-
ing cells, the proastrocytic function of NFIA/B might be
Neuron
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(A–I) Double immunolabeling with NFIA/Olig2 (A and B and E and F) and NFIB/Olig2 (C and D and G and H) at the indicated time points in murine
embryonic spinal cord. (E–H) Yellow arrows indicate NFI+/Olig2+ cells, and white arrow indicate NFI2/Olig2+ cells. Quantitative analysis (I) is de-
rived from five sections per embryo times three embryos per time point. (J–O and V) Experiments in E13.5 rat cortical progenitors, cultured in 20
ng/ml FGF-2 to suppress spontaneous astrocyte differentiation. NFIA (L, M, and V) and NFIB (V) promote GFAP expression. This activity is sup-
pressed by Olig2 (N, O, and V). All transfections included a GFP plasmid as an internal reference. (P–U and W) Experiments in E13.5 rat cortical
progenitors, withdrawn from mitogen to promote astrocyte differentiation. Suppression of GFAP expression by Olig2 (R, S, and W) is reversed by
cotransfection with NFIA or NFIB (T–W). Values in (V) and (W) represent three independent experiments performed in triplicate. (X) Western blot of
immunoprecipitated HEK293 cell extracts. ‘‘IP’’ indicates antibodies used for immunoprecipitation; aNFIA and aMyc indicate antibodies used for
Western blotting for NFIA and Olig2-myc, respectively. Lanes 3, 5, and 10 serve as negative controls. Lanes 8 and 9 indicate co-IP of NFIA-HA or
Olig2-myc, by antibodies to Olig2-myc (amyc) or NFIA (aNFIA), respectively. Error bars indicate SD.inhibited. Since Olig2 normally suppresses astrocyte
differentiation (Zhou and Anderson, 2002; Gabay et al.,
2003; Fukuda et al., 2004), we investigated whether Olig2
might functionally antagonize NFIA/B. To test this
hypothesis, we first asked whether inclusion of excess
Olig2 could block the ability of NFIA overexpression toaccelerate the appearance of GFAP in vivo. Whereas
electroporation of NFI genes alone caused an 11- to
12-fold increase in the number of GFAP-expressing cells
in the chick embryonic spinal cord (Figure 6Z), co-
electroporation with Olig2 suppressed this phenotype
by w6-fold (Figure 6Z, NFIA or B + Olig2). These data
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ability of NFI genes to promote GFAP expression in vivo.
The complexity of the in vivo environment, as well as
the time delay between electroporation (E2) and analysis
(E7), made it difficult to exclude the possibility that the
inhibitory influence of Olig2 on NFIA function in vivo re-
flected a non-cell-autonomous, or other indirect, effect.
We therefore carried out analogous experiments in cul-
tured rat E13.5 cortical progenitor cells grown in FGF-2
(Burrows et al., 1997; Gabay et al., 2003). Overexpres-
sion of exogenous NFIA or NFIB in such cultures caused
a >7-fold and 5-fold increase, respectively, in the pro-
portion of transfected (GFP+) cells coexpressing GFAP
(Figures 7K and 7M, arrows; Figure 7V), consistent
with our in vivo findings (Figure 6). Strikingly, cotransfec-
tion of Olig2 inhibited this proastrocytic effect of NFIA/B
(Figures 7O and 7V). Staining for neuronal markers indi-
cated that the inhibitory effect of Olig2 on astrocyte dif-
ferentiation was not due to any effect of Olig2 to pro-
mote neurogenesis or cell death (data not shown).
Thus, Olig2 can block the ability of NFIA/B to promote
GFAP expression in vitro, as well as in vivo (Figure 6Z).
Astrogliogenesis Depends on the Relative Levels
of Olig2 and NFIA/B
The foregoing experiments suggested that Olig2 can
suppress the proastrocytic activity of NFIA/B. To inves-
tigate whether this antagonism can be prevented by
elevating the level of NFIA/B, we exploited the fact that
transfection of Olig2 suppresses the spontaneous astro-
cyte differentiation caused by mitogen withdrawal from
cultured E13.5 cortical progenitors (Gabay et al., 2003).
Immunostaining experiments confirmed that these pro-
genitors express endogenous NFIA and NFIB (data not
shown). If astrocyte differentiation in these cultures is
promoted by endogenous NFIA/B, then one would pre-
dict that augmenting the levels of NFIA/B should over-
ride the antiastrocytic effect of Olig2 in this system.
To test this hypothesis, an Olig2 expression construct
was transfected into E13.5 cortical progenitors alone or
in combination with NFIA/B expression constructs.
FGF-2 was withdrawn from the cultures to promote
GFAP expression. In control cultures, under such condi-
tions 55% of transfected (GFP+) cells differentiated into
GFAP-expressing astrocytes (Figure 7Q, arrows;
Figure 7W, GFP). Transfection of Olig2 alone sup-
pressed astrocytic differentiation to 17% GFAP+/GFP+
cells (Figure 7S, arrows; Figure 7W, Olig2), confirming
our previous report (Gabay et al., 2003). By contrast,
supplementation of Olig2 transfections with excess
NFIA or NFIB restored the expression of GFAP to control
levels (Figure 7U, arrows; Figure 7W, Olig2 + NFIA or +
NFIB). These data suggest that increasing the total level
of NFIA/B expression can override the suppression of
astrocyte differentiation by Olig2 in vitro. Taken to-
gether, these in vitro data suggest that the suppression
of NFIA function by Olig2 is dependent on the relative
levels of these two factors.
Olig2 functions as a transcriptional repressor (Novitch
et al., 2001; Zhou et al., 2001) and therefore could, in
principle, directly repress NFIA transcription (Figures
S5E–S5L). However, such a mechanism cannot explain
its ability to inhibit the proastroglial function of trans-
fected NFIA, which is expressed under the control ofa constitutive promoter. This latter inhibition could,
therefore, be indirect, e.g., via transcriptional repression
of a requisite NFIA cofactor. Alternatively, it could in-
volve a direct, posttranscriptional inhibition of NFIA.
As a first step toward distinguishing these alternatives,
we investigated whether there might be a physical inter-
action between Olig2 and NFIA. Human embryonic kid-
ney (HEK293) cells were cotransfected with Olig2 and
NFIA expression constructs, each bearing distinct epi-
tope tags. Extracts from these cells were immunopre-
cipitated with antibodies to the Olig2 or NFIA tag and
Western blotted with antibodies to NFIA or the Olig2
tag, respectively. The results of this IP-Western experi-
ment indicated that NFIA was found in Olig2 immuno-
precipitates and vice versa (Figure 7X, lane9-aNFIA
and lane8-amyc). These data provide evidence of
a physical association between the two proteins and
suggest that the functional antagonism of NFIA by
Olig2 is likely to involve a direct protein-protein interac-
tion, rather than an indirect mechanism.
Discussion
Progenitor cells throughout the developing CNS un-
dergo a developmental switch, during which they cease
generating neurons and give rise to glia (Kessaris et al.,
2001). A fundamental unresolved issue has been the ex-
tent to which these two processes are intrinsically cou-
pled by a single factor or are governed by distinct mech-
anisms (Figure 1A). Here we show that NFI transcription
factors instruct glial-fate specification in vivo, but are
unable to inhibit neurogenesis. Conversely, Notch effec-
tors, while sufficient to inhibit neurogenesis, are insuffi-
cient to promote glial-fate specification. These data
suggest that the abrogation of neurogenesis and the ini-
tiation of gliogenesis are controlled by genetically sepa-
rable mechanisms. Nevertheless, the two processes are
linked by the requirement of NFIA for the maintenance of
Notch effector expression during the gliogenic phase
(Figures 8C and 8D). This requirement allows NFIA to
help maintain the undifferentiated progenitor pool that
is the cellular substrate for gliogenesis. Thus, the glio-
genic switch is controlled by a distributed, rather than
a unitary, molecular mechanism (Figure 9B). This core
mechanism initially operates in both astrocyte and oli-
godendrocyte progenitors (Figure 9C, early). At later
stages, however, the function of NFIA/B must be antag-
onized in the oligodendrocyte lineage, because NFIA/B
also promote terminal astrocyte differentiation. We
show that this antagonism is mediated by Olig2 (Fig-
ure 9D, late) and is likely direct. These data suggest a
transcriptional logic for the gliogenic switch that, initially,
imposes an intrinsic astrocytic bias, which is ultimately
overridden in the oligodendrocyte lineage by Olig2.
NFIA/B Are ‘‘Pro-Glial’’ Genes
The JAK-STAT and the BMP/SMAD pathways have both
been shown to promote expression of GFAP (Bonni
et al., 1997; Nakashima et al., 1999). However, GFAP
is a late-appearing terminal astrocyte differentiation
marker that is not expressed until w5 days after APs
have migrated out of the VZ. Consistent with this, recent
data indicate that, in murine spinal cord, phosphorylated
(active) STAT3 is not strongly expressed in the gray
Neuron
964Figure 8. Summary of Principal Results
(A–D) Rectangles represent ventricular zone;
for simplicity, the surrounding gray matter is
omitted. ‘‘cE3,’’ etc., represent states of chick
embryo development. The pattern of expres-
sion of the indicated markers at different
times is shown in control embryos (A), and
in NFIA gain-of-function ([B]; eNFIA = exoge-
nous NFIA), loss-of-function (C), or loss-of-
function plus Notch effector gain-of-function
([D]; eHES = exogenous HES) embryos. The
order in which the progenitor markers Sox9,
Pax7, and Pax6 are listed does not indicate
their spatial relationship. Note that NFIA
RNAi causes loss of HES5 and progenitor
markers at E5 but not at E4 (C) and that HES
GOF rescues progenitor markers but not
gliogenesis.matter until E17.5 (Yan et al., 2004), the time at which
GFAP is first detectable. It has been suggested that
Sox9 may control the initiation of gliogenesis (Stoltet al., 2003). However, misexpression of Sox9 in vivo
does not cause precocious induction of GLAST in the
VZ or premature emigration of APs (B.D. and D.J.A.,Figure 9. Summary of Spinal Cord Marker
Expression and Functions of NFIA/B during
Gliogenesis
(A) Schematic illustrating the changes in
marker expression during spinal cord devel-
opment, and the temporal domains of func-
tion of key regulatory genes (above dia-
grams). Both mouse (m) and chick (c) stages
are shown. INs, interneurons; MNs, moto-
neurons; VZ, ventricular zone; MZ, marginal
zone; APs, astrocyte precursors; OPs, oligo-
dendrocyte precursors. Markers expressed
at multiple stages are converted to white
lettering after their initial expression (e.g.,
Pax6, Sox9) to avoid obscuring the names of
later-appearing markers. With the exception
of Olig2, the positioning of the markers in the
VZ does not imply any spatial localization.
(B) Illustration depicting the distributed model
for gliogenic switch (see also Figure 1A3). Pro-
genitors with and without neurogenic capac-
ity are indicated by P1 and P2, respectively.
(C and D) Schematic illustrating roles of
NFIA in gliogenesis. (C) At early stages, NFIA
promotes glial-fate specification in both the
oligodendrocyte and astrocyte lineages (solid
arrows) and maintains Olig2 expression and
progenitor status via Notch effectors (dashed
arrow). (D) At later stages, NFIA promotes
terminal astrocyte differentiation, a function
antagonized in the oligodendrocyte lineage
by Olig2.
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the first transcription factor to be identified that is both
necessary and sufficient to initiate glial-fate specifica-
tion in the VZ and therefore qualifies as a ‘‘pro-glial’’
gene.
Because NFIA/B promote expression of GLAST in the
VZ and because GLAST-expressing cells in the cortical
VZ have been characterized as ‘‘radial glia’’ (Malatesta
et al., 2000; Alvarez-Buylla et al., 2001; Gotz and Barde,
2005), it could be argued that NFIA/B specify a ‘‘radial
glial’’ phenotype. However, radial glial cell bodies are,
by definition, located in the VZ, and misexpression of
NFIA/B also promotes precocious emigration of APs
into the gray matter (Figure 2 and Figure S2). Since mi-
grating APs also express GLAST (Figure S5), expression
of GLAST is not a defining characteristic of radial glia.
These data argue that NFIA/B initiate generic glial-fate
specification in the spinal cord rather than promoting
a radial glial phenotype.
NFIA Is Required to Maintain the Undifferentiated
Progenitor Pool in the Spinal Cord
An unexpected result of the present studies is the obser-
vation that knock-down of NFIA caused the loss of ex-
pression of multiple markers of progenitors throughout
the VZ, including Pax6, Pax7, Sox9, and Olig2. In the ab-
sence of NFIA, these progenitors eventually die. How-
ever, the loss of marker expression does not simply re-
flect cell death, since it is observed even when such
death is attenuated by expression of the antiapoptotic
protein p35. This phenotype is doubly striking, given
that all of these markers are initially expressed prior to
the induction of NFIA (Mansouri and Gruss, 1998; Bris-
coe et al., 2000; Kessaris et al., 2001). These data reveal
a fundamental, latent change in the mechanisms that
regulate the expression of progenitor markers in the
VZ, from NFIA-independent to NFIA-dependent.
Our data suggest that the requirement for NFIA in
progenitor maintenance is mediated, at least in part,
by its requirement for the continued expression of Notch
effectors such as HES5. In the absence of NFIA, VZ
progenitors differentiate inappropriately into neurons,
a phenotype similar to that obtained by inhibiting Notch
signaling with Su(H)DBM. Misexpression of HES, or of
NotchICD + Su(H), is sufficient to rescue this NFIA-RNAi
phenotype, as well as to rescue the expression of pro-
genitor markers (Figures 8C and 8D). In addition, misex-
pression of HES is sufficient to rescue the death of pro-
genitors caused by NFIA knock-down, consistent with
recent data demonstrating a role for Notch signaling in
maintaining progenitor survival (Mason et al., 2006). Im-
portantly, however, misexpression of Notch effectors
does not rescue the requirement of NFIA for induction
of GLAST (Figures 8A and 8D). These data suggest
that NFIA coordinates the transition from neurogenesis
to gliogenesis via two distinct functions: a permissive
requirement for the inhibition of neurogenesis, which
maintains an undifferentiated progenitor pool, and the
instructive promotion of a glial differentiation program
(Figure 9B).
Such a coordinated function for NFIA is logical, in ret-
rospect. What is surprising is that the expression of HES
genes in the VZ is initiated independently of NFIA (at E3–
E4) but subsequently becomes dependent on this factor(Figure 8C). It is not clear whether this transition reflects
a shift in HES regulation, from Notch-dependent to
Notch-independent/NFIA-dependent, or simply the im-
position of an additional requirement for NFIA. The upre-
gulation of HES5 expression 1–2 days prior to induction
of NFIA may serve to ensure that the inhibition of neuro-
genesis is well underway, before activation of the glio-
genic program commences (Figure 8A, cE4; also see
Figure 9A). The subsequent shift to NFIA dependency
may then provide that progenitors which express HES
genes do not simply remain undifferentiated, but rather
become specified for a glial fate.
NFIA/B Promote Terminal Astrocyte Differentiation
Previous studies have shown that adult mice deficient in
NFIA or NFIB exhibit a reduction in cortical GFAP ex-
pression (das Neves et al., 1999; Steele-Perkins et al.,
2005), as well as a reduction in the number of midline
glia (Shu et al., 2003). It was not clear, however, whether
this phenotype reflected a change in gene expression,
cell death, or decreased astrocyte production. Our
data indicate that misexpression of NFIA or NFIB is suf-
ficient to accelerate GFAP expression in astrocytic pre-
cursors by several days, in vivo and in vitro. Further-
more, in E18.5 embryos lacking either NFIA or NFIB,
a reduction in spinal cord GFAP expression was ob-
served, without any change in the number of astrocytes
(as measured by the expression of NFIB and NFIA, re-
spectively). These data argue that NFIA/B promote the
terminal differentiation of astrocytes, in addition to their
earlier, pro-glial function. This role is likely to be direct,
as functional NFI-binding sites have been found in the
GFAP promoter (Cebolla and Vallejo, 2006). It will be im-
portant in the future to determine the relationship be-
tween NFI genes and other regulators of GFAP expres-
sion, such as the JAK/STAT and BMP/SMAD pathways
(Bonni et al., 1997; Nakashima et al., 1999) and DNA
methylation (Takizawa et al., 2001; Fan et al., 2005).
Olig2 Antagonizes the Proastrocytic Function
of NFIA/B in the Oligodendrocyte Lineage
While NFIA is required for the glial-fate specification of
both oligodendrocyte and astrocyte progenitors in the
VZ (Figure 9C, early), its later function to promote termi-
nal differentiation is specific to the astroglial lineage.
These observations raise the question of how NFIA/B
can be initially required in the oligodendrocyte lineage,
if they ultimately promote astrocyte differentiation. In
a subset of OPs, NFIA/B are downregulated. Further-
more, Olig2 can antagonize the proastrocytic function
of NFIA/B, when both factors are coexpressed. These
data suggest that in OPs, the proastrocytic function of
NFIA/B may be suppressed by Olig2 (Figure 9, late).
This antagonism is gene dosage-dependent, since ele-
vating the level of NFIA/B can override the inhibition of
astrocyte differentiation by Olig2. Therefore, we cannot
exclude the possibility that elevated levels of NFIA/B
override the effects of Olig2 and drive some OPs to an
astrocytic fate. The dosage-sensitivity of Olig2-NFIA an-
tagonism (Figures 7V and 7W) could explain why a small
percentage of astrocytes are derived from Olig2+ pro-
genitors in embryos in which one copy of Olig2 has
been replaced by an inducible Cre recombinase line-
age-tracer (Masahira et al., 2006).
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NFIA and Olig2 is not yet clear. Our coimmunoprecipita-
tion experiments indicate that these two proteins can
physically associate, when cotransfected in cultured
HEK cells. However, further experiments will be required
to investigate the nature of the interaction between NFIA
and Olig2, and its consequences for transcriptional reg-
ulation by these two proteins. Nevertheless, the obser-
vation that NFIA and Olig2 can physically associate sug-
gests that the functional antagonism between these two
proteins is likely to be direct rather than indirect.
Unitary versus Distributed Mechanisms
of Glial-Fate Determination
The data presented here suggest that in vertebrates, the
gliogenic switch is controlled by a distributed mecha-
nism. The Notch pathway and its effectors function to
suppress neurogenesis, while the pro-glial factors
NFIA/B promote glial-fate specification. However, these
two processes are coupled, via the requirement of NFIA
for maintenance of Notch effector expression (Fig-
ure 9B). Such a distributed mechanism may help to ex-
plain several areas of confusion in the literature. First,
there have been conflicting reports as to whether misex-
pression of Notch effectors promotes gliogenesis or
rather maintains progenitor status (reviewed in Louvi
and Artavanis-Tsakonas, 2006). One explanation for
this discrepancy might be that if Notch effectors are mis-
expressed in a context where NFIA/B are expressed,
then they will promote gliogenesis; alternatively, if
NFIA/B are not yet expressed, then Notch effectors
will inhibit differentiation and maintain progenitor status.
Second, there has been controversy about where and
when cells expressing glial markers actually become
committed to glial fate. In the adult subventricular
zone, some GFAP+ cells can generate neurons (Doetsch
et al., 1999). In the embryonic cortex, radial glia have
been shown to generate neurons even after they ex-
press markers such as GLAST and brain lipid binding
protein (Malatesta et al., 2000; Noctor et al., 2001; An-
thony et al., 2004); reviewed in Gotz and Barde, 2005).
In the spinal cord, however, transplantation and other
experiments have shown that Olig2+ cells are restricted
to glial fates by the time they express GLAST (Richard-
son et al., 2000; Mukouyama et al., 2006). Thus, not all
GLAST+ cells possess neurogenic capacity, and not all
GFAP+ cells are committed to a glial fate. A distributed
mechanism such as we describe here could explain such
context-dependent uncoupling between glial/radial glial
marker expression and neurogenic capacity.
The mechanisms that control the loss of neurogenic
capacity are not fully understood: for example, Notch
signaling can either reversibly (Gaiano et al., 2000) or
irreversibly (Morrison et al., 2000) inhibit neurogenesis;
the difference between these two modes is not clear.
Identification of the mechanisms that promote the
irreversible loss of neurogenic capacity, and of the
cues that promote expression of NFIA/B, should help
to explain the relationship between the specification
of glial identity and commitment to a glial fate. A deeper
understanding of these mechanisms may, in turn,
permit the controlled reversion of adult glial cells to neu-
rogenic status for therapeutic purposes (Kondo and
Raff, 2000).Supplemental Data
The Supplemental Data for this article can be found online at http://
www.neuron.org/cgi/content/full/52/6/953/DC1/.
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